Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Sep 14 - Sep 19
Multi-Pathway Research Focus Supports investigation of overlapping signaling systems
The combination was first characterized for safety and pharmacokinetics in a Phase 1b trial, [4] then advanced into the Phase 3a REDEFINE program
Unlike many peptides that have only injectable research data, GHK-Cu has been tested in published human clinical trials specifically as a topical application with outcomes that compared favorably against gold-standard actives
Reaching these doses requires eight to sixteen weeks of gradual escalation for each component, with coordination to avoid escalating both simultaneously
US$ 25.98
US$ 28.02
US$ 24.90
US$ 23.93
US$ 21.02
US$ 26.83
